Bacteriology and Inflammation in Bronchiectasis (BISER)
Bronchiectasis
About this trial
This is an interventional treatment trial for Bronchiectasis focused on measuring bacteriology, inflammation, bronchiectasis, exacerbation
Eligibility Criteria
Inclusion Criteria:
- Patients of either sex and age between 18 and 70 years
Exclusion Criteria:
- Patient judged to have poor compliance
- Female patient who is lactating or pregnant
- Patients having concomitant severe systemic illnesses (i.e. coronary heart disease, cerebral stroke, uncontrolled hypertension, active gastric ulcer, malignant tumor, hepatic dysfunction, renal dysfunction)
- Miscellaneous conditions that would potentially influence efficacy assessment, as judged by the investigators
- Participation in another clinical trial within the preceding 3 months
Sites / Locations
- State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical CollegeRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Fluroquinolones
Beta-lactamase inhibitor
The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.